|
Active substance |
Epcoritamab |
|
Holder |
AbbVie Belgium SA/NV |
|
Status |
Running |
|
Indication |
Epcoritamab monotherapy for the treatment of relapsed or refractory Follicular Lymphoma (FL), previously treated with at least 2 lines of systemic antineoplastic therapy (3L) in case of a reported and documented progression of disease within 24 months from initial treatment initiation (POD24) OR with at least 3 lines of systemic antineoplastic therapy (4L+). |
|
Public documents |
|
|
Last update |
09/10/2025 |
Tepkinly®
Last updated on